The novel TYK2 inhibitor deucravacitinib was recently approved by the FDA to treat patients with plaque psoriasis and is currently being tested in clinical trials for the treatment of other inflammatory disorders (21). The gene discussed is TYK2; the disease is psoriasis vulgaris.